PRESS RELEASE published on 04/15/2025 at 19:48, 1 year 6 months ago Informations privilégiées / Autres communiqués Augmentation du montant du contrat de liquidité de Medincell confié à Rothschild Martin Maurel pour accompagner l'augmentation des volumes de titres échangés quotidiennement Contrat De Liquidité Rothschild Martin Maurel Augmentation Titres Medincell
PRESS RELEASE published on 04/15/2025 at 19:48, 1 year 6 months ago Inside Information / Other news releases Medincell increases liquidity contract resources by 600,000 euros with Rothschild Martin Maurel to support higher trading volumes Liquidity Contract Rothschild Martin Maurel Amendment Medincell Trading Volumes
BRIEF published on 03/10/2025 at 11:54, 1 year 7 months ago Adage Capital dépasse les 5% dans MEDINCELL Euronext Paris Franchissement De Seuil Actions Medincell Adage Capital
BRIEF published on 03/10/2025 at 11:54, 1 year 7 months ago Adage Capital exceeds 5% in MEDINCELL Euronext Paris Actions Threshold Crossing Medincell Adage Capital
PRESS RELEASE published on 03/10/2025 at 11:49, 1 year 7 months ago Franchissement de seuil Déclaration de franchissement de seuil par Adage Capital Management LP pour l'acquisition d'actions MEDINCELL sur le marché Franchissement De Seuil Marché Acquisition D'actions Medincell Adage Capital Management LP
BRIEF published on 02/25/2025 at 23:08, 1 year 8 months ago FDA Accepts Application for UZEDY's Use in Treating Bipolar I Disorder FDA Approval Medincell Teva Pharmaceuticals UZEDY Bipolar I Disorder
BRIEF published on 02/25/2025 at 23:08, 1 year 8 months ago La FDA accepte la demande d'utilisation d'UZEDY dans le traitement du trouble bipolaire I Approbation De La FDA Teva Pharmaceuticals Médinecell OUZEDY Trouble Bipolaire I
PRESS RELEASE published on 02/25/2025 at 23:03, 1 year 8 months ago Inside Information / Other news releases Teva and Medincell announce FDA acceptance of UZEDY(R) risperidone for bipolar I disorder treatment, expanding indications for this long-acting injectable antipsychotic FDA Medincell Teva UZEDY Bipolar I Disorder
PRESS RELEASE published on 02/25/2025 at 23:03, 1 year 8 months ago Informations privilégiées / Autres communiqués Teva et Medincell annoncent l'acceptation par la FDA d'une demande de nouveau médicament supplémentaire pour UZEDY® en tant que traitement du trouble bipolaire I FDA Medincell Teva UZEDY Bipolar I Disorder
BRIEF published on 02/19/2025 at 08:33, 1 year 8 months ago Medincell réussit son Offre Globale à 42,9 millions d'euros Levée De Fonds Investisseurs Internationaux Medincell Offre Globale Technologie BEPO®
Published on 10/30/2026 at 23:35, 5 hours 6 minutes ago Prospect Ridge Announces Closing of Critical Metals Flow-through Unit Private Placement
Published on 10/30/2026 at 23:30, 5 hours 11 minutes ago Revolve Enters into Definitive Agreement to Acquire Three Project, 6 MW Battery Storage Portfolio in Ontario
Published on 10/30/2026 at 20:47, 7 hours 54 minutes ago CoTec Holdings Corp. Comments on Share Trading
Published on 10/30/2026 at 19:00, 9 hours 41 minutes ago Electric Royalties Ltd. Announces Application for Warrant Extension
Published on 10/30/2026 at 15:30, 13 hours 11 minutes ago Bluejay Diagnostics Announces 1-for-4 Reverse Stock Split
Published on 10/30/2026 at 22:49, 5 hours 52 minutes ago EQS-Adhoc: STRATEC SELLS LOSS-MAKING BUSINESS, RECOGNIZES IMPAIRMENTS, AND AMENDS GUIDANCE
Published on 10/30/2026 at 18:38, 10 hours 3 minutes ago EQS-Adhoc: Starcom Holding AD publishes Interim Q3 2026 Financial Report
Published on 10/30/2026 at 23:00, 5 hours 41 minutes ago BIOPHYTIS REPORTS FIRST- HALF 2026 RESULTS AND PROVIDES AN UPDATE ON ITS STRATEGY
Published on 10/30/2026 at 23:00, 5 hours 41 minutes ago Biophytis publie les résultats du premier semestre 2026 et fait le point sur sa stratégie
